Edition:
United Kingdom

Pluristem Therapeutics Inc (PSTI.OQ)

PSTI.OQ on NASDAQ Stock Exchange Capital Market

1.42USD
14 Dec 2017
Change (% chg)

$0.03 (+2.16%)
Prev Close
$1.39
Open
$1.38
Day's High
$1.44
Day's Low
$1.38
Volume
25,859
Avg. Vol
107,035
52-wk High
$2.12
52-wk Low
$1.04

Chart for

About

Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its... (more)

Overall

Beta: 0.11
Market Cap(Mil.): $145.24
Shares Outstanding(Mil.): 97.47
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Pluristem enters agreement with Tel Aviv Sourasky Medical Center to conduct phase i/ii trial in steroid-refractory chronic GvHD

* Pluristem enters into agreement with Tel Aviv Sourasky Medical Center to conduct phase i/ii trial in steroid-refractory chronic GvHD Source text for Eikon: Further company coverage:

06 Nov 2017

BRIEF-PLURISTEM PRICES PUBLIC OFFERING OF COMMON STOCK ON THE TEL AVIV STOCK EXCHANGE

* PLURISTEM ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK ON THE TEL AVIV STOCK EXCHANGE

30 Oct 2017

BRIEF-Pluristem extends trial for treatment of insufficient hematopoietic recovery

* Following approval of israel’s ministry of health, Pluristem extends its trial of plx-r18 to treat insufficient Hematopoietic recovery after bone marrow transplant and opens clinical centers in Israel

26 Oct 2017

BRIEF-Pluristem expands its reach in the treatment of impaired hematopoietic systems

* Pluristem expands its reach in the treatment of impaired hematopoietic systems with a European patent covering PLX-R18 in chemotherapy, ARS, genetic disorders and autoimmune diseases Source text for Eikon: Further company coverage:

23 Oct 2017

BRIEF-FDA grants Pluristem Orphan Drug Designation for its PLX-R18 cell therapy

* FDA grants Pluristem Orphan Drug Designation for its PLX-R18 cell therapy as treatment for acute radiation syndrome Source text for Eikon: Further company coverage:

19 Oct 2017

BRIEF-Pluristem receives positive feedback from FDA and EMA as co prepares for Phase III trial of PLX-PAD

* Pluristem receives positive feedback from FDA and EMA as company prepares for Phase III trial of PLX-PAD to support recovery from hip fracture

26 Sep 2017

BRIEF-U.S. FDA grants fast track designation to Pluristem's PLX-PAD for treating Critical Limb Ischemia

* U.S. FDA grants fast track designation to Pluristem's PLX-PAD for the treatment of Critical Limb Ischemia (cli)

18 Sep 2017

BRIEF-Pluristem Therapeutics awarded two new patents in Hong Kong

* Awarded two new patents in Hong Kong for critical limb ischemia and muscle regeneration

13 Sep 2017

BRIEF-U.S. DOD to conduct studies of Pluristem’s PLX-R18 in a new ARS project

* U.S. Department of Defense to conduct studies of Pluristem’s PLX-R18 in a new ars project for use before radiation exposure

16 Aug 2017

BRIEF-Pluristem's ‍ARS study's new data shows hematological deficiencies even at low radiation levels​

* New data from ARS study shows significant hematological deficiencies even at low radiation levels; PLX-R18 supports hematological recovery​ Source text for Eikon: Further company coverage:

26 Jul 2017

Earnings vs. Estimates